Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis ...

Incyte (INCY) “announced that the FDA has approved Opzelura cream 1.5%, a topical Janus kinase inhibitor, for the short-term and non-continuous ...

Rosacea can cause redness, breakouts, and discomfort. Here, dermatologists share moisturizers that may help color-correct ...

U.S. Dermocosmetics Market Forecast to Reach USD 10.71 Billion by 2032, Growing at a 7.67% CAGR.Austin, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Dermocosmetics Market Size Analysis: According to S&S Insider ...

Back in the late 1800s, medicine didn't have all the answers. People died from infections that today we might cure with pills ...